Reaction Details |
| Report a problem with these data |
Target | Bile acid receptor |
---|
Ligand | BDBM28529 |
---|
Substrate/Competitor | BDBM10852 |
---|
Meas. Tech. | FXR Co-transfection Assay |
---|
pH | 7±n/a |
---|
Temperature | 295.15±n/a K |
---|
EC50 | 600±n/a nM |
---|
Comments | 100% efficacy. |
---|
Citation | Flatt, B; Martin, R; Wang, TL; Mahaney, P; Murphy, B; Gu, XH; Foster, P; Li, J; Pircher, P; Petrowski, M; Schulman, I; Westin, S; Wrobel, J; Yan, G; Bischoff, E; Daige, C; Mohan, R Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR). J Med Chem52:904-7 (2009) [PubMed] Article |
---|
More Info.: | Get all data from this article, Solution Info, Assay Method |
---|
|
Bile acid receptor |
---|
Name: | Bile acid receptor |
Synonyms: | BAR | Bile acid receptor FXR | FXR | Farnesol receptor HRR-1 | HRR1 | NR1H4 | NR1H4_HUMAN | Nuclear receptor subfamily 1 group H member 4 | RIP14 | RXR-interacting protein 14 | Retinoid X receptor-interacting protein 14 | farnesoid x receptor |
Type: | Nuclear Receptor |
Mol. Mass.: | 55916.24 |
Organism: | Homo sapiens (Human) |
Description: | Q96RI1 |
Residue: | 486 |
Sequence: | MVMQFQGLENPIQISPHCSCTPSGFFMEMMSMKPAKGVLTEQVAGPLGQNLEVEPYSQYS
NVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTK
KPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCV
MDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEG
RDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLI
LTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSD
LLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEK
LQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLC
EIWDVQ
|
|
|
BDBM28529 |
---|
BDBM10852 |
---|
Name | BDBM28529 |
Synonyms: | Azepino[4,5-b]indole, 1 | ethyl 3-[(4-fluorophenyl)carbonyl]-1H,2H,3H,6H-azepino[4,5-b]indole-5-carboxylate |
Type | Small organic molecule |
Emp. Form. | C22H19FN2O3 |
Mol. Mass. | 378.3963 |
SMILES | CCOC(=O)C1=CN(CCc2c1[nH]c1ccccc21)C(=O)c1ccc(F)cc1 |t:5| |
Structure |
|